Smith & Nephew SNATS, Inc. (NYSE:SNN - Get Free Report) crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $31.06 and traded as high as $32.66. Smith & Nephew SNATS shares last traded at $32.4660, with a volume of 2,679,835 shares.
Wall Street Analyst Weigh In
SNN has been the topic of several research reports. Morgan Stanley lowered shares of Smith & Nephew SNATS from an "overweight" rating to an "equal weight" rating in a report on Wednesday, September 2nd. Wall Street Zen upgraded shares of Smith & Nephew SNATS from a "hold" rating to a "buy" rating in a report on Sunday, September 13th. Barclays cut shares of Smith & Nephew SNATS from an "equal weight" rating to an "underweight" rating in a research report on Wednesday, August 5th. Bank of America downgraded Smith & Nephew SNATS from a "buy" rating to a "neutral" rating in a research report on Tuesday, September 8th. Finally, BTIG Research began coverage on Smith & Nephew SNATS in a research note on Monday, August 31st. They set a "neutral" rating on the stock. One analyst has rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Smith & Nephew SNATS currently has a consensus rating of "Hold" and a consensus target price of $31.91.
Read Our Latest Stock Report on Smith & Nephew SNATS
Smith & Nephew SNATS Stock Performance
The business has a fifty day moving average of $28.41 and a 200-day moving average of $31.06. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 2.14.
Institutional Trading of Smith & Nephew SNATS
Several institutional investors and hedge funds have recently modified their holdings of the business. Ethic Inc. boosted its holdings in shares of Smith & Nephew SNATS by 10.5% during the third quarter. Ethic Inc. now owns 29,168 shares of the medical equipment provider's stock worth $786,000 after purchasing an additional 2,762 shares during the period. Alps Advisors Inc. lifted its stake in Smith & Nephew SNATS by 4.3% in the third quarter. Alps Advisors Inc. now owns 25,790 shares of the medical equipment provider's stock worth $695,000 after acquiring an additional 1,054 shares during the period. Ashton Thomas Private Wealth LLC boosted its holdings in Smith & Nephew SNATS by 15.4% in the third quarter. Ashton Thomas Private Wealth LLC now owns 10,676 shares of the medical equipment provider's stock valued at $288,000 after acquiring an additional 1,427 shares in the last quarter. Trek Financial LLC boosted its holdings in Smith & Nephew SNATS by 14.6% in the third quarter. Trek Financial LLC now owns 9,721 shares of the medical equipment provider's stock valued at $262,000 after acquiring an additional 1,241 shares in the last quarter. Finally, Vise Technologies Inc. lifted its position in shares of Smith & Nephew SNATS by 8.6% in the 3rd quarter. Vise Technologies Inc. now owns 17,847 shares of the medical equipment provider's stock worth $481,000 after purchasing an additional 1,409 shares during the period. Hedge funds and other institutional investors own 25.64% of the company's stock.
Smith & Nephew SNATS Company Profile
(
Get Free Report)
Smith & Nephew plc is a global medical technology company that develops and manufactures products used by healthcare professionals to treat injuries, manage wounds and restore patients' mobility. Founded in 1856 by Thomas James Smith in Hull, England, the company has grown from a pharmacy business into an international healthcare manufacturer.
The company operates across three principal areas: orthopaedics, sports medicine and ear, nose and throat (ENT), and advanced wound management.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Smith & Nephew SNATS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew SNATS wasn't on the list.
While Smith & Nephew SNATS currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
